STOCK TITAN
  1. Home
  2. Sec-filings
  3. ASND
  4. [Form 3] Ascendis Pharma A/S Initial Statement of Beneficial Ownership

Ascendis Pharma (ASND) officer reports warrants, RSUs and shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Ascendis Pharma A/S officer Jensen Flemming Steen filed an initial ownership report showing a mix of ordinary shares, warrants, and restricted stock units tied to the company’s equity. He holds 19,460 ordinary shares directly, including American Depositary Shares where each ADS represents one ordinary share.

His derivative position includes fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 respectively. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest over time beginning on March 1, 2027 and have no expiration date.

Positive

  • None.

Negative

  • None.
Insider JENSEN FLEMMING STEEN
Role See Remarks
Type Security Shares Price Value
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Warrants -- -- --
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Restricted Stock Units -- -- --
holding Ordinary Shares -- -- --
Holdings After Transaction: Warrants — 84,259 shares (Direct); Restricted Stock Units — 16,995 shares (Direct); Ordinary Shares — 19,460 shares (Direct)
Footnotes (6)
  1. F1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
  2. F2. The warrants are fully vested and currently exercisable.
  3. F3. The restricted stock units vest on March 1, 2027 and have no expiration date.
  4. F4. Each restricted stock unit represents a contingent right to receive one ADS.
  5. F5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
  6. F6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.

FAQ

What did Ascendis Pharma (ASND) disclose in Jensen Flemming Steen’s Form 3?
Ascendis Pharma reported officer Jensen Flemming Steen’s existing equity holdings. The filing details his direct ownership of ordinary shares, fully vested warrants, and multiple restricted stock unit grants that vest beginning March 1, 2027, outlining his overall long-term equity exposure to the company.

How many Ascendis Pharma ordinary shares does Jensen Flemming Steen directly own?
He directly owns 19,460 ordinary shares of Ascendis Pharma. The filing notes that these holdings include American Depositary Shares, with each ADS representing one ordinary share, providing a baseline view of his direct, non-derivative equity position in the company.

What warrant positions are reported for Jensen Flemming Steen in Ascendis Pharma (ASND)?
He holds fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares. Exercise prices are 62.1700, 108.0000, 176.2800 and 139.6500, with expiration dates between December 2028 and December 2031.

What restricted stock units does Jensen Flemming Steen hold in Ascendis Pharma?
He holds RSUs covering 4,246, 3,197 and 9,552 ordinary shares. Each restricted stock unit represents a contingent right to receive one ADS and vests in scheduled annual installments beginning on March 1, 2027, with no expiration date specified for these awards.

Do the warrants and RSUs in this Ascendis Pharma Form 3 involve new transactions?
The Form 3 lists holdings but shows no buy or sell transactions. All entries are classified as holdings, with transaction codes unspecified, indicating this filing serves as an initial snapshot of existing positions rather than reporting new market activity.

How do the Ascendis Pharma RSUs for Jensen Flemming Steen vest over time?
Some RSUs vest fully on March 1, 2027, while others vest in two or three equal annual installments starting that date. This creates a multi-year vesting schedule that gradually delivers ADSs, aligning a portion of his compensation with future company performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
JENSEN FLEMMING STEEN
(Last)(First)(Middle)
C/O ASCENDIS PHARMA A/S
TUBORG BOULEVARD 12
(Street)
HELLERUPDK-2900
(City)(State)(Zip)
UNITED STATES
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares(1)19,460D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants (2)12/11/2028Ordinary Shares20,000$62.17D
Warrants (2)12/10/2029Ordinary Shares27,000$108D
Warrants (2)12/10/2030Ordinary Shares22,755$176.28D
Warrants (2)12/09/2031Ordinary Shares14,504$139.65D
Restricted Stock Units (3) (3)Ordinary Shares4,246(4)D
Restricted Stock Units (5) (5)Ordinary Shares3,197(4)D
Restricted Stock Units (6) (6)Ordinary Shares9,552(4)D
Explanation of Responses:
1. Includes American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share.
2. The warrants are fully vested and currently exercisable.
3. The restricted stock units vest on March 1, 2027 and have no expiration date.
4. Each restricted stock unit represents a contingent right to receive one ADS.
5. The restricted stock units vest in two equal annual installments beginning on March 1, 2027.
6. The restricted stock units vest in three equal annual installments beginning on March 1, 2027.
Remarks:
EVP & Product Supply and Quality
/s/ Michael Wolff Jensen as attorney-in-fact for Flemming Jensen03/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR